News

Kanagawa, Japan, 19^th May 2026 – FIMECS, Inc. (“FIMECS”), a private biotechnology company pioneering a new class of medicines through targeted protein degradation, today announced that Dr. Kanae Gamo, CEO has been invited to deliver an oral presentation at the World TPD & Induced Proximity South Korea Summit 2026, taking place in Seoul, South Korea, from June 9^th–11^th, 2026. In addition, Yukiko Nakamura, Vice President of Business Development, will participate in a panel discussion on collaboration and business development in the TPD field.

Presentation Details:
Title: Expanding the Landscape of TPD: E3-agnostic approach to unlock the E3 Ligase Space
Presenter: Dr. Kanae Gamo, CEO
Date: June 11^th, 2026

In her presentation, Dr. Gamo will focus on an E3-agnostic approach to expand the accessible E3 ligase landscape and systematically identify novel ligase binders. She will highlight how integrated deconvolution workflows and diverse chemical scaffold exploration enable the efficient generation of ligands applicable to both bifunctional degraders and molecular glues. The talk will also discuss the use of ligases with favorable expression profiles to support improved selectivity, safety, and oral drug potential.

Panel Discussion Details:
Speaker: Yukiko Nakamura, Vice President, Business Development
Date: June 11^th, 2026

The panel session will cover topics including the structuring of biopharma partnerships, industry perspectives on innovation in Asia, and key considerations for building and scaling a TPD-focused biotech. The session will feature speakers from leading organizations including Amgen, Pin Therapeutics, and Ubix Therapeutics.

The World TPD & Induced Proximity South Korea Summit is a leading international conference focused on emerging modalities such as targeted protein degradation and induced proximity approaches. The meeting brings together global experts from academia and industry to discuss advances in TPD, E3 ligase biology, and next-generation drug discovery strategies, while also providing a valuable platform to engage with the rapidly growing TPD community in Asia and explore global collaborations emerging from the region.
More information: https://worldtpd-kr.com/

About FIMECS, Inc.
FIMECS, Inc. is a wholly-owned subsidiary of RaQualia Pharma (TSE:4579). The company is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. By integrating proprietary E3 ligase binders and the RaPPIDS™ platform, FIMECS can discover drug candidates that induce the degradation of disease-relevant proteins. This drug discovery platform enable the company to deliver innovative drugs to patients worldwide through both internal and collaboration projects. https://www.fimecs.com/eng/

# # #

FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
E-mail: info@fimecs.com